Document Detail

Optimal cervical cytology mass screening interval for cervical cancer.
MedLine Citation:
PMID:  23053319     Owner:  NLM     Status:  Publisher    
OBJECTIVE: To identify the optimal interval for repeat cervical cytology testing for screening of cervical cancer and dysplasia in healthy female adults. DESIGN AND METHODS: A retrospective cohort study was conducted on 3,804 apparently healthy females without known cervical cancer at baseline from 2005 to 2010. Participants underwent annual health checkups, including cervical cytology testing. This data did not contain human papillomavirus status. Participants with cytological abnormality underwent further examination, including biopsy, to check for cervical cancer. The generalized estimating equation (GEE) was performed to analyze the longitudinal data. RESULTS: In the groups <40, 40-49, 50-59 and ≥60 years old, the 5-year cumulative incidences (95 % CI) of cytological abnormality were 11.2 % (8.8-13.9 %), 7.6 % (6.2-9.3 %), 4.4 % (3.3-5.7 %) and 2.8 % (1.8-4.2 %), respectively, and the cumulative incidences of cervical cancer were 0.9 % (0.3-2.0 %), 0.1 % (0.0-0.4 %), 0.1 % (0.0-0.5 %) and 0 %, respectively. The odds ratios of the incidence for cervical cancer and cervical dysplasia per year, with GEE models, were 1.5 (95 % CI:1.1-2.0), 1.2 (95 % CI:0.8-1.9), 2.2 (95 % CI:0.5-10.3) and 0 for cervical cancer, and 1.3 (95 % CI:1.2-1.5), 1.3 (95 % CI:1.2-1.5), 1.3 (95 % CI:1.1-1.5) and 1.4 (95 % CI:0.9-2.0) for cervical dysplasia, respectively. CONCLUSIONS: For patients under 40 years old, the screening for cervical cancer every 2 years should be considered, while for patients of 40-59 years old screening every 2 or 3 years should be considered. Females over 60 years old may only need repeat screening every 5 years.
Daiki Kobayashi; Osamu Takahashi; Chikako Hikosaka; Tomoya Okubo; Tsuguya Fukui
Related Documents :
25074879 - Creation of a diagnostic wait times measurement framework based on evidence and consensus.
23373359 - Preoperative staging of rectal cancer: role of 3d endorectal ultrasonography.
24363529 - Application of quantitative estimates of fecal hemoglobin concentration for risk predic...
24156679 - Prognostic significance of the preoperative serum levels of soluble form of endoglin in...
23725269 - Risk assessment to guide prostate cancer screening decisions: a cost-effectiveness anal...
23584349 - Quality indicators in the management of bladder cancer.
13116019 - Present status of serological tests for cancer.
7517409 - Effect of zatosetron on ipecac-induced emesis in dogs and healthy men.
19679619 - Aging and cancer: converging routes to disease prevention.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-11
Journal Detail:
Title:  Archives of gynecology and obstetrics     Volume:  -     ISSN:  1432-0711     ISO Abbreviation:  Arch. Gynecol. Obstet.     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-11     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8710213     Medline TA:  Arch Gynecol Obstet     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Division of General Internal Medicine, Department of Medicine, St. Luke's International Hospital, Tokyo, Japan,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Validity and efficacy of office hysteroscopy before in vitro fertilization treatment.
Next Document:  Early FDG PET response assessment of preoperative radiochemotherapy in locally advanced rectal cance...